Total Payments
$2.0M
2024 Payments
$25,385
Companies
53
Transactions
1,164
Medicare Patients
209
Medicare Billing
$32,083
Payment Breakdown by Category
Research$1.4M (68.7%)
Other$448,660 (22.2%)
Consulting$99,328 (4.9%)
Travel$59,049 (2.9%)
Food & Beverage$24,159 (1.2%)
Education$448.45 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.4M | 125 | 68.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $424,442 | 244 | 21.0% |
| Consulting Fee | $99,328 | 29 | 4.9% |
| Travel and Lodging | $59,049 | 133 | 2.9% |
| Honoraria | $24,175 | 8 | 1.2% |
| Food and Beverage | $24,159 | 619 | 1.2% |
| Education | $448.45 | 5 | 0.0% |
| Grant | $43.95 | 1 | 0.0% |
Payments by Type
Research
$1.4M
125 transactions
General
$631,645
1,039 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $778,479 | 126 | $0 (2024) |
| Amgen Inc. | $430,681 | 277 | $0 (2023) |
| Genentech, Inc. | $166,268 | 18 | $0 (2019) |
| Lilly USA, LLC | $150,038 | 191 | $0 (2023) |
| Allergan, Inc. | $128,287 | 63 | $0 (2022) |
| Dr.Reddy's Laboratories,Inc. | $112,924 | 18 | $0 (2019) |
| ABBVIE INC. | $66,785 | 168 | $0 (2024) |
| Eli Lilly and Company | $55,178 | 37 | $0 (2024) |
| Biohaven Pharmaceuticals, Inc. | $30,089 | 33 | $0 (2021) |
| Biohaven Pharmaceutical Holding Company Ltd. | $22,469 | 31 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $25,385 | 51 | ABBVIE INC. ($13,423) |
| 2023 | $31,997 | 125 | Lilly USA, LLC ($9,838) |
| 2022 | $64,739 | 141 | Biohaven Pharmaceutical Holding Company Ltd. ($22,469) |
| 2021 | $135,032 | 135 | Amgen Inc. ($36,055) |
| 2020 | $132,022 | 143 | Allergan, Inc. ($41,093) |
| 2019 | $390,302 | 274 | Teva Pharmaceuticals USA, Inc. ($128,002) |
| 2018 | $426,155 | 181 | Amgen Inc. ($167,350) |
| 2017 | $814,201 | 114 | Teva Pharmaceuticals USA, Inc. ($483,243) |
All Payment Transactions
1,164 individual payment records from CMS Open Payments — Page 1 of 47
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | — | In-kind items and services | $3,200.00 | Research |
| Study: NURTEC CLINICAL PUBLICATION PROGRAM • Category: PAIN | ||||||
| 12/12/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $24.42 | General |
| Category: NEUROLOGY | ||||||
| 12/06/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $31.49 | General |
| 11/27/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $2,370.60 | Research |
| Study: Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants • Category: Neurology | ||||||
| 11/27/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $71.55 | Research |
| Study: Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants • Category: Neurology | ||||||
| 11/19/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $16.21 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $20.74 | General |
| Category: PAIN | ||||||
| 10/24/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $30.28 | General |
| Category: NEUROLOGY | ||||||
| 10/17/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $32.49 | General |
| Category: NEUROSCIENCE | ||||||
| 10/11/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $31.84 | General |
| Category: NEUROSCIENCE | ||||||
| 10/10/2024 | Genentech USA, Inc. | Ocrevus Zunovo (Biological) | Food and Beverage | In-kind items and services | $29.93 | General |
| Category: Immunology | ||||||
| 09/24/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $22.56 | General |
| Category: NEUROSCIENCE | ||||||
| 09/18/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Food and Beverage | In-kind items and services | $41.45 | General |
| Category: Musculoskeletal | ||||||
| 09/06/2024 | REVANCE THERAPEUTICS, INC. | DAXI (Drug) | Food and Beverage | In-kind items and services | $35.95 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 09/04/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $27.64 | General |
| Category: NEUROSCIENCE | ||||||
| 09/04/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $2.50 | General |
| Category: NEUROSCIENCE | ||||||
| 08/29/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $17.89 | General |
| Category: PAIN | ||||||
| 08/27/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $32.86 | General |
| Category: NEUROSCIENCE | ||||||
| 08/23/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | — | In-kind items and services | $780.00 | Research |
| Study: NURTEC CLINICAL PUBLICATION PROGRAM • Category: PAIN | ||||||
| 08/22/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $23.48 | General |
| Category: NEUROLOGY | ||||||
| 08/21/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $16.18 | General |
| Category: PAIN | ||||||
| 08/15/2024 | ABBVIE INC. | QULIPTA (Drug), BOTOX | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: NEUROSCIENCE | ||||||
| 08/06/2024 | Eli Lilly and Company | — | — | In-kind items and services | $730.01 | Research |
| Study: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY | ||||||
| 08/01/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $29.34 | General |
| Category: Neurology | ||||||
| 07/18/2024 | PFIZER INC. | ZAVZPRET (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: ZAVEGEPANT CLINICAL PUBLICATION PROGRAM • Category: PAIN | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TV48125-CNS-30049/50/51 | Teva Pharmaceuticals USA, Inc. | $341,057 | 5 |
| PRODROMAL TO MILD AD | Genentech, Inc. | $166,268 | 18 |
| Phase 2 Episodic Migraine Prophylaxis EMP | Amgen Inc. | $131,047 | 2 |
| TV48125-CNS | Teva Pharmaceuticals USA, Inc. | $117,522 | 5 |
| P2 Migraine Proof of Concept | Amgen Inc. | $87,837 | 2 |
| A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled,Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments | Teva Pharmaceuticals USA, Inc. | $84,355 | 2 |
| A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | Allergan Inc. | $72,438 | 13 |
| A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Epidosic Cluster Headache | Teva Pharmaceuticals USA, Inc. | $52,571 | 4 |
| A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments | Teva Pharmaceuticals USA, Inc. | $43,804 | 7 |
| A Study to Explore the Long-Term Safety and Efficacy of TEV-48125 (Fremanezumab) for the Prevention of Cluster Headache (ENFORCE) | Teva Pharmaceuticals USA, Inc. | $41,954 | 4 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Tolerability, and Safety Study of DFN-15 in Episodic Migraine With or Without Aura Oral Celecoxib | Dr.Reddy's Laboratories,Inc. | $37,043 | 6 |
| Dr. Reddy 1007754 | Dr.Reddy's Laboratories,Inc. | $28,682 | 4 |
| DFN-11-CD-004A Multicenter, Randomized, Double-Blind, Palcebo-Controlled Efficacy, Tolerability and Safety Study of DFN-11 Sumitriptan 3mg in Episodic Migraine with or without Aura | Dr.Reddy's Laboratories,Inc. | $27,868 | 2 |
| TV48125-CNS-30056/57/58 | Teva Pharmaceuticals USA, Inc. | $24,663 | 3 |
| A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | Allergan, Inc. | $22,373 | 8 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of DFN-02 Sumatriptan Nasal Spray 10 mg in Episodic Migraine With or Without Aura | Dr.Reddy's Laboratories,Inc. | $19,308 | 5 |
| AN OPEN-LABEL, MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN SUBJECTS WITH IDIOPATHIC GENERALIZED EPILEPSY PHASE 3 | UCB Biosciences Inc. | $14,890 | 4 |
| Phase 3 Pivotal EMP (ARISE) | Amgen Inc. | $13,644 | 1 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $7,820 | 1 |
| Medication Overuse Headache Study (MOH)_ | Amgen Inc. | $7,312 | 1 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of Fremanezumab (TEV-48125) Versus Placebo for the Preventive Treatment of Chronic Migraine | Teva Pharmaceuticals USA, Inc. | $6,668 | 1 |
| Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine | Teva Pharmaceuticals USA, Inc. | $5,184 | 1 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA | Allergan Inc. | $5,000 | 1 |
| NURTEC CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,980 | 2 |
| A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLO | UCB Biosciences Inc. | $3,766 | 2 |
| A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN SUBJECTS WITH IDIOPATHIC GENERALIZED EP | UCB Biosciences Inc. | $3,298 | 1 |
| ZAVEGEPANT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE - THE CONQUER STUDY | Eli Lilly and Company | $3,171 | 2 |
| Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | Ipsen Innovation | $2,442 | 2 |
| A PHASE 3B MULTICENTER, SINGLE-ARM, OPEN-LABEL SAFETY STUDY OF LY2951742 -GALCANEZUMAB- IN PATIENTS WITH EPISODIC OR CHRONIC CLUSTER HEADACHE | Eli Lilly and Company | $2,175 | 2 |
| RIMEGEPANT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,880 | 2 |
| ZAVZPRET CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| Phase 3 Pivotal EMP (STRIVE) | Amgen Inc. | $923.35 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $750.00 | 1 |
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY | Eli Lilly and Company | $730.01 | 1 |
| A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | Eli Lilly and Company | $548.00 | 1 |
| RIMEGEPANT SULFATE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC CLUSTER HEADACHE | Eli Lilly and Company | $247.35 | 1 |
| A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 WITH A LONG-TERM OPEN-LABEL EXTENSION IN PATIENTS WITH CHRONIC CLUSTER HEADACHE | Eli Lilly and Company | $247.35 | 1 |
| AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR | Eli Lilly and Company | $150.00 | 1 |
| A PHASE 3, LONG-TERM, OPEN-LABEL SAFETY STUDY OF LY2951742 IN PATIENTS WITH MIGRAINE | Eli Lilly and Company | $52.80 | 1 |
| Evaluation of ischemic cardiovascular and cerebrovascular adverse events by 10-year cardiovascular | Amgen Inc. | $49.88 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 75 | 102 | $26,650 | $12,533 |
| 2022 | 3 | 80 | 98 | $24,100 | $12,062 |
| 2021 | 1 | 33 | 46 | $9,200 | $5,285 |
| 2020 | 1 | 21 | 23 | $4,600 | $2,203 |
Total Patients
209
Total Services
269
Medicare Billing
$32,083
Procedure Codes
8
All Medicare Procedures & Services
8 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 42 | 63 | $12,600 | $6,765 | 53.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 21 | 21 | $10,500 | $3,957 | 37.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 18 | $3,550 | $1,811 | 51.0% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 34 | 43 | $8,600 | $4,731 | 55.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 30 | 39 | $7,800 | $4,288 | 55.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 16 | 16 | $7,700 | $3,043 | 39.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 33 | 46 | $9,200 | $5,285 | 57.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 21 | 23 | $4,600 | $2,203 | 47.9% |
About Dr. David Kudrow, MD
Dr. David Kudrow, MD is a Neurology healthcare provider based in Santa Moncia, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1952407488.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Kudrow, MD has received a total of $2.0M in payments from pharmaceutical and medical device companies, with $25,385 received in 2024. These payments were reported across 1,164 transactions from 53 companies. The most common payment nature is "" ($1.4M).
As a Medicare-enrolled provider, Kudrow has provided services to 209 Medicare beneficiaries, totaling 269 services with total Medicare billing of $32,083. Data is available for 4 years (2020–2023), covering 8 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Santa Moncia, CA
- Active Since 09/15/2006
- Last Updated 08/18/2010
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1952407488
Products in Payments
- Fremanezumab (Biological) $483,243
- Aimovig (Biological) $185,885
- Non-Covered Product (Drug) $166,268
- Ajovy (Drug) $127,349
- UBRELVY (Drug) $74,805
- EMGALITY (Drug) $61,451
- NURTEC ODT (Drug) $56,922
- AJOVY (Drug) $53,264
- REYVOW (Drug) $31,200
- Vimpat (Drug) $21,954
- VYEPTI (Biological) $15,369
- QULIPTA (Drug) $13,528
- ELYXYB - CELECOXIB (Drug) $9,995
- AJOVY (Biological) $7,094
- Zembrace (Drug) $4,856
- ZAVZPRET (Drug) $4,140
- AIMOVIG (Biological) $3,592
- Dysport (Drug) $2,442
- ELYXYB - celecoxib (Drug) $2,425
- TREXIMET (Drug) $1,994
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.